Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Shahrzad Rafiei"'
Autor:
Kasia M. Dillon, Raie T. Bekele, Zsofia Sztupinszki, Timothy Hanlon, Shahrzad Rafiei, Zoltan Szallasi, Atish D. Choudhury, Kent W. Mouw
Publikováno v:
npj Precision Oncology, Vol 6, Iss 1, Pp 1-6 (2022)
Abstract PARP inhibitors were recently approved for treatment of molecularly-defined subsets of metastatic castrate-resistant prostate cancer (mCRPC) patients. Although the PARP inhibitor olaparib was approved for use in patients with a mutation in o
Externí odkaz:
https://doaj.org/article/e1053094a65e49b4bf91021177e964ef
Supplementary Tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eee89692b69cf389e6794066d0adb32a
https://doi.org/10.1158/1541-7786.22515465.v1
https://doi.org/10.1158/1541-7786.22515465.v1
Although androgen deprivation therapy (ADT) is an effective treatment for metastatic prostate cancer, incurable castration-resistant prostate cancer (CRPC) inevitably develops. Importantly, androgen receptor (AR) continues to be critical for prostate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b67205aa3ab8218ef951c86c4f111bf0
https://doi.org/10.1158/1541-7786.c.6541092
https://doi.org/10.1158/1541-7786.c.6541092
Supplementary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9397ac5fb5d0aac446fba4827956e145
https://doi.org/10.1158/1541-7786.22515468
https://doi.org/10.1158/1541-7786.22515468
Autor:
Kent W. Mouw, Eliezer M. Van Allen, Justin H. Hwang, Steven P. Balk, William C. Hahn, Atish D. Choudhury, Bose S. Kochupurakkal, Cora Ricker, Jihye Park, Haitham A. Elmarakeby, Mu-Yan Cai, David Liu, Kenyon Fitzpatrick, Shahrzad Rafiei
siRNA and sgRNA sequences
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8460da43c93b89ab89511f0e220059e4
https://doi.org/10.1158/0008-5472.22423412
https://doi.org/10.1158/0008-5472.22423412
Autor:
Kent W. Mouw, Eliezer M. Van Allen, Justin H. Hwang, Steven P. Balk, William C. Hahn, Atish D. Choudhury, Bose S. Kochupurakkal, Cora Ricker, Jihye Park, Haitham A. Elmarakeby, Mu-Yan Cai, David Liu, Kenyon Fitzpatrick, Shahrzad Rafiei
Alterations in DNA damage response (DDR) genes are common in advanced prostate tumors and are associated with unique genomic and clinical features. ATM is a DDR kinase that has a central role in coordinating DNA repair and cell-cycle response followi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::778fc7bf8e7269895b1fade1cb37e016
https://doi.org/10.1158/0008-5472.c.6511496.v1
https://doi.org/10.1158/0008-5472.c.6511496.v1
Autor:
Kent W. Mouw, Eliezer M. Van Allen, Justin H. Hwang, Steven P. Balk, William C. Hahn, Atish D. Choudhury, Bose S. Kochupurakkal, Cora Ricker, Jihye Park, Haitham A. Elmarakeby, Mu-Yan Cai, David Liu, Kenyon Fitzpatrick, Shahrzad Rafiei
Immunofluorescence and IR survival data; additional methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::233f6aba383663a027a31392309bb7fb
https://doi.org/10.1158/0008-5472.22423415
https://doi.org/10.1158/0008-5472.22423415
Autor:
Steven P. Balk, Shahrzad Rafiei, William C. Hahn, Mu Yan Cai, Haitham Elmarakeby, Eliezer M. Van Allen, David Liu, Kenyon Fitzpatrick, Kent W. Mouw, Cora A. Ricker, Justin H. Hwang, Atish D. Choudhury, Bose Kochupurakkal, Jihye Park
Publikováno v:
Cancer Res
Alterations in DNA damage response (DDR) genes are common in advanced prostate tumors and are associated with unique genomic and clinical features. ATM is a DDR kinase that has a central role in coordinating DNA repair and cell-cycle response followi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a76479dd3e038bedb62ebf01d69593cd
https://doi.org/10.1158/0008-5472.can-19-3126
https://doi.org/10.1158/0008-5472.can-19-3126
Autor:
Kasia M. Dillon, Raie T. Bekele, Zsofia Sztupinszki, Timothy Hanlon, Shahrzad Rafiei, Zoltan Szallasi, Atish D. Choudhury, Kent W. Mouw
Publikováno v:
NPJ precision oncology. 6(1)
PARP inhibitors were recently approved for treatment of molecularly-defined subsets of metastatic castrate-resistant prostate cancer (mCRPC) patients. Although the PARP inhibitor olaparib was approved for use in patients with a mutation in one of fou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c74cb9ffae10a057f74ca968aac02b8d
https://pubmed.ncbi.nlm.nih.gov/35768576
https://pubmed.ncbi.nlm.nih.gov/35768576
Publikováno v:
Molecular cancer research : MCR. 17(1)
Although androgen deprivation therapy (ADT) is an effective treatment for metastatic prostate cancer, incurable castration-resistant prostate cancer (CRPC) inevitably develops. Importantly, androgen receptor (AR) continues to be critical for prostate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6a9494e7a10aec385765284629e58df
https://pubmed.ncbi.nlm.nih.gov/30224544
https://pubmed.ncbi.nlm.nih.gov/30224544